

Amendments

Kindly enter the following amendments.

In the Claims:

Please cancel claims 3-36, 39-52 and 54-94 without prejudice to or disclaimer of the subject matter contained therein. Applicants reserve the right to prosecute the subject matter of these claims in one or more continuing and/or divisional applications.

Please substitute the following claim 1 for the pending claim 1:

B1 *Sub C7* 1. (Once amended) A method of treating amyloidosis in a subject, said method comprising administering to said subject an effective amount of (a) a metal chelator selected from the group consisting of: bathocuproine, bathophenanthroline, penacillamine, tetraethylenediamine (TETA), N,N,N',N'-tetrakis[2-pyridyl-methyl]ethylenediamine (TPEN) or hydrophobic derivatives thereof; and (b) one or more pharmaceutically acceptable carriers or diluents; for a time and under conditions to bring about said treatment; and wherein said chelator reduces, inhibits or otherwise interferes with Abeta peptide (A β)-mediated production of radical oxygen species.

Please substitute the following claim 37 for the pending claim 37:

B2 *Sub C9* 37. (Once amended) A pharmaceutical composition for treatment of conditions caused by amyloidosis, A β -mediated reactive oxygen species (ROS) formation, or both, comprising: (a) a metal chelator selected from the group consisting of: bathocuproine, bathophenanthroline, penacillamine, TETA, and TPEN, or hydrophobic derivatives thereof; and (b) one or more pharmaceutically acceptable carriers or diluents.